Previous 10 | Next 10 |
Dermata Therapeutics Inc. (DRMA) is expected to report for Q3 2023
SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at t...
2023-08-31 08:17:07 ET Dollar General DG -16% after Q2 release . OKYO Pharma ( OKYO ) -14% . Top KingWin ( TCJH ) -10% . ReTo Eco-Solutions ( RETO ) -11% . Beneficient ( BENF ) -10% . Digital Brands Group ( DBGI ) -9% . ...
2023-08-30 10:00:13 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-30 08:17:19 ET Top KingWin ( TCJH ) +36% . Digital Brands Group ( DBGI ) +32% . Globalstar ( GSAT ) +12% . Dermata Therapeutics ( DRMA ) +13% . LexinFintech ( LX ) +8% Q2 earnings call release BioLineRx ...
2023-08-11 16:26:51 ET More on Dermata Therapeutics Dermata Therapeutics announces $1.8M offering priced ATM Dermata climbs ~28% after update on acne candidate Dermata Therapeutics launches $5M securities offering Dermata climbs after positive early stag...
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 - - Phase 3 STAR-1 study is projected to start enrolling patients in the 2H 2023 - SAN DIEGO, C...
- FDA established key elements of the DMT310 Phase 3 clinical program and delineated a potential regulatory pathway for approval of DMT310 - -The DMT310 Phase 3 program will consist of two pivotal trials, STAR-1 and STAR-2 ( Spongilla Treatment of Acne Research Study )- - The first ...
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invi...
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) - - DMT310 significantly reduced inflammatory lesion...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...